View our comprehensive portfolio of products for drug development and patient diagnosis and monitoring
Our products are trusted worldwide in research, clinical, and commercial laboratory settings.
Functional and biomarker assays for the exploration of every angle of the complement system
Our cell-based bioassays are based on iLite® technology – a cleverly designed cell-based assay system with reporter gene readouts
AAV Neutralizing Antibody (NAb), Total Antibody (TAb), and Complement Activation assays designed to provide a comprehensive view of vector immunogenicity
Solutions for detecting and semi-quantitating IgG antibodies against CCP
Our extensive CRO Services offer bioanalysis, biomarker discovery, and GMP QC testing.
With over 30 years of experience in autoimmune diagnostics, our ISO15189-certified specialist laboratory can help you reach the correct diagnosis. We also provide testing services and support for therapeutic drug monitoring.
Let us develop a custom iLite® cell line tailored to your needs.
Our cell services are highly reliable and innovative, tailored to your manufacturing needs
Immunogenic responses, where antibodies are produced by the immune system as a protective response, can adversely affect the pharmacokinetics, bioavailability, and efficacy of biopharmaceuticals, and may even neutralize the activity of the drug.
Many different factors influence the immunogenicity of biopharmaceuticals. Although in most cases, an immune response to a biopharmaceutical has little or no clinical impact, they can pose several potential risks for the patient, particularly in the case of an Anti-Drug Antibody (ADA) and neutralizing antibody (NAb) response.
Fill out the form to get you're own copy of the poster listing various factors that affect the immunogenicity of biopharmaceuticals.
Potential pitfalls are summarized and listed according to the increased risk of immunogenic response - use it as a guide of factors to consider when assessing and designing drug compounds.